Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6939297 | 0.98 | KDM4E (0.35) | KDM4EMEN1ALDH1A1HPGDAPOBEC3A | |
| Bromide SCHEMBL8386845 | 0.79 | ALDH1A1 (0.40) | KDM4EMEN1ALDH1A1HPGDAPOBEC3A | |
| Bromide SCHEMBL2954185 | 0.70 | KMT2A (0.56) | KDM4EMEN1ALDH1A1HPGDAPOBEC3A | |
| Bromide SCHEMBL6226270 | 0.66 | KMT2A (0.38) | KDM4EMEN1ALDH1A1HPGDAPOBEC3A | |
| Bromide SCHEMBL7400580 | 0.65 | TKT (0.50) | — | |
| Bromide SCHEMBL7400578 | 0.64 | TKT (0.49) | — | |
| Bromide SCHEMBL2954205 | 0.63 | ALDH1A1 (0.54) | KDM4EMEN1ALDH1A1HPGDAPOBEC3A | |
| Bromide SCHEMBL8385551 | 0.63 | ALDH1A1 (0.54) | KDM4EMEN1ALDH1A1HPGDAPOBEC3A | |
| Bromide SCHEMBL8446341 | 0.63 | MEN1 (0.38) | KDM4EMEN1ALDH1A1HPGDAPOBEC3A | |
| Bromide SCHEMBL2955912 | 0.63 | MEN1 (0.30) | MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1576093-A4 | 3-DEOXYGLUCOSONE AND SKIN | DYNAMIS THERAPEUTICS INC (US) | 2009-07-08 | — | — | EP | claimed |
| US-20070065443-A1 | Fructoseamine 3 kinase and the formation of collagen and elastin | DYNAMIS THERAPEUTICS, INC. | 2007-03-22 | — | — | US | claimed |
| EP-1753861-A2 | FRUCTOSEAMINE 3 KINASE AND THE FORMATION OF COLLAGEN AND ELASTIN | Dynamis Therapeutics, Inc. (US) | 2007-02-21 | — | — | EP | claimed |
| EP-1576093-A2 | 3-DEOXYGLUCOSONE AND SKIN | Dynamis Therapeutics, Inc. (US) | 2005-09-21 | — | — | EP | claimed |
| WO-2005079463-A2 | FRUCTOSEAMINE 3 KINASE AND THE FORMATION OF COLLAGEN AND ELASTIN | DYNAMIS THERAPEUTICS, INC. (US) | 2005-09-01 | — | — | WO | claimed |
| US-20050159383-A1 | Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) | DYNAMIS THERAPEUTICS, INC. | 2005-07-21 | — | — | US | claimed |
| US-20030219440-A1 | 3-deoxyglucosone and skin | DYNAMIS THERAPEUTICS, INC. | 2003-11-27 | — | — | US | claimed |
| US-RE38330-E1 | Preventing and reversing advanced glycosylation endproducts | ALTEON INC. | 2003-11-25 | — | — | US | claimed |
| WO-2003089601-A2 | 3-DEOXYGLUCOSONE AND SKIN | DYNAMIS THERAPEUTICS, INC. (US) | 2003-10-30 | — | — | WO | claimed |
| EP-0808163-B1 | USE OF THIAZOLIUM COMPOUNDS FOR PREVENTING AND REVERSING THE FORMATION OF ADVANCED GLYCOSYLATION ENDPRODUCTS | ALTEON INC (US) | 2003-07-23 | — | — | EP | claimed |
| US-5656261-A | USING A THIAZOLIUM COMPOUND | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1997-08-12 | — | — | US | claimed |
| US-20100310482-A1 | 3-Deoxyglucosone And Skin | DYNAMIS THERAPEUTICS, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-7749503-B2 | 3-deoxyglucosone and skin | DYNAMIS THERAPEUTICS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-7671019-B2 | Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) | DYNAMIS THERAPEUTICS, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7622117-B2 | 3-deoxyglucosone and skin | DYNAMIS THERAPEUTICS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-6007865-A | FOR INHIBITING AND REVERSING NONENZYMATIC CROSS-LINKING (PROTEIN AGING), TREATING KIDNEY DAMAGE AND TREATING COMPLICATIONS OF DIABETES, PREVENTING FOOD SPOILAGE | ALTEON INC. | 1999-12-28 | — | — | US | disclosed |
| US-5853703-A | Preventing and reversing the formation of advanced glycosylation endproducts | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1998-12-29 | — | — | US | disclosed |
| EP-0808163-A2 | USE OF THIAZOLIUM COMPOUNDS FOR PREVENTING AND REVERSING THE FORMATION OF ADVANCED GLYCOSYLATION ENDPRODUCTS | ALTEON, INC. (US) | 1997-11-26 | — | — | EP | disclosed |
| US-5656261-A | USING A THIAZOLIUM COMPOUND | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1997-08-12 | — | — | US | disclosed |
| WO-1996022095-A2 | USE OF THIAZOLIUM COMPOUNDS FOR PREVENTING AND REVERSING THE FORMATION OF ADVANCED GLYCOSYLATION ENDPRODUCTS | ALTEON INC. (US) | 1996-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070065443-A1 | Fructoseamine 3 kinase and the formation of collagen and elastin | FN3K, PDXK, COLGALT1 | KDM4E 1956/4885MEN1 1069/4885ALDH1A1 927/4885 |
| US-20100310482-A1 | 3-Deoxyglucosone And Skin | DPM1, G6PD, UGGT1 | KDM4E 897/4885MEN1 1559/4885ALDH1A1 383/4885 |
| US-20030219440-A1 | 3-deoxyglucosone and skin | DPM1, G6PD, UGGT1 | KDM4E 897/4885MEN1 1559/4885ALDH1A1 383/4885 |
| US-20050159383-A1 | Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) | AGER, GLA, GALE | KDM4E 441/4885MEN1 3627/4885ALDH1A1 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.